- RecruitingPHASE3
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
This study, called iFIT, helps doctors find the best treatments for older myeloma patients. It checks how well standard NHS treatment works and looks at your fitness level. Then, it uses this information to decide the next steps, aiming to improve your care.
For: Multiple Myeloma (MM) · Plasma Cell Leukemia (PCL)United Kingdom - Active not recruitingPHASE2
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine, teclistamab, for people with multiple myeloma that has come back or hasn't responded to other treatments. It's looking at how well the medicine works at a specific dose.
For: Hematological MalignanciesUnited States · Belgium · Canada - Active not recruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new combination treatment, teclistamab with daratumumab (Tec-Dara), against standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new combination works better.
For: Multiple MyelomaUnited States · Argentina · Belgium - Active not recruitingPHASE3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
This study looks at new drug combinations for multiple myeloma that has come back or isn't responding to previous treatments. It compares different ways of combining talquetamab with other medicines to see which works best for people who have already tried certain common myeloma drugs.
For: Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
For: Haematological Malignancy · Acute Myeloid Leukemia · Non Hodgkin LymphomaUnited States · France · Spain - RecruitingPHASE3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
This study is looking at a new treatment, JNJ-79635322, for multiple myeloma, a type of blood cancer. It compares this new treatment with an existing one (Teclistamab) to see which works better for people whose cancer has returned or hasn't responded to previous treatments.
For: Multiple MyelomaUnited States · Australia · Canada - Active not recruitingPHASE2
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
This study is looking at new ways to treat newly diagnosed multiple myeloma. It compares different combinations of new and existing medicines to see which ones work best to control the cancer and potentially lead to long-lasting remission.
For: Multiple MyelomaUnited States · Australia · Brazil - Active not recruitingPHASE1
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
This study is testing a new medicine called teclistamab, combined with other treatments, for people with multiple myeloma. Scientists want to find the safest and best doses of these combinations to treat the disease effectively.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
This study is looking into two new medicines, talquetamab and teclistamab, for people with multiple myeloma that has come back or isn't responding to other treatments. It aims to find the safest and most effective way to use them together, especially for those with hard-to-treat forms of the disease.
For: Multiple MyelomaUnited States · Australia · Canada - RecruitingPHASE4
Plan Development for Giving Teclistamab in the Outpatient Setting
This study is looking at how to give a cancer medicine called teclistamab to people with multiple myeloma at home or at an outpatient clinic. It also wants to understand how this affects their caregivers.
For: Multiple Myeloma · Relapsed Cancer · Refractory CancerCanada - Active not recruitingPHASE1
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
This study looks at new ways to treat a blood cancer called multiple myeloma. It combines an existing medicine, Daratumumab, with newer ones (Talquetamab or Teclistamab), sometimes with Pomalidomide. The main goal is to find safe doses and see how well these combinations work.
For: Multiple MyelomaUnited States · Canada · Germany - Active not recruitingPHASE2
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
This study looks at new treatments for younger adults with newly diagnosed multiple myeloma. It tests combinations of medications like teclistamab and talquetamab, depending on whether a small amount of cancer is still present after initial treatment. The goal is to find better ways to manage the disease.
For: Multiple MyelomaFrance - RecruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
This study is looking at new drug combinations for people recently diagnosed with a type of blood cancer called multiple myeloma. It compares two new treatments, Teclistamab or Talquetamab, each given with standard drugs, against the usual standard treatment, to see which works best.
For: Multiple MyelomaUnited States · Australia · Austria - Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
This study looks at how well new treatments called teclistamab and talquetamab work for people in the UK with a specific type of blood cancer called multiple myeloma, when these treatments are given outside of formal clinical trials. It's about understanding real-world results.
For: Relapsed/Refractory Multiple Myeloma (RRMM)Denmark · France · Germany - Active not recruitingPHASE1
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
This study looks at a new way of making Teclistamab, a medicine for a blood cancer called multiple myeloma. We're checking if the new version works the same inside your body as the old one, to make sure it's safe and effective.
For: Multiple MyelomaUnited States · Australia · Canada - Active not recruitingPHASE3
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new treatment, teclistamab, with existing therapies for multiple myeloma that has come back or not responded to previous treatments. It aims to see how well teclistamab works and if it's safe for people with this condition.
For: Relapsed or Refractory Multiple MyelomaUnited States · Australia · Austria - RecruitingPHASE3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
This study looks at new treatments for multiple myeloma, a type of blood cancer. We're testing if teclistamab, alone or with lenalidomide, works better than lenalidomide alone after a stem cell transplant to stop the cancer from coming back.
For: Multiple MyelomaUnited States · Argentina · Australia - Not yet recruitingPHASE3
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
This study is for adults with a type of blood cancer called multiple myeloma that has come back or not responded to previous treatments. It compares a new medicine combination (Etentamig plus Pomalidomide) with standard treatments to see if it's safe and helps improve the disease.
For: Relapsed or Refractory Multiple MyelomaUnited States · Australia · Canada